Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.46 |
| ▸ | TYR | P14679 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.40 |
| ▸ | YARS1 | P54577 | 2/20 | 0.38 |
| ▸ | ACACB | O00763 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28703154 | 0.80 | TYR (0.58) | SLC7A5TYRDPP4HDAC8YARS1 | |
| SCHEMBL27859073 | 0.80 | TYR (0.58) | SLC7A5TYRDPP4HDAC8YARS1 | |
| Hydrochloric Acid SCHEMBL27841331 | 0.79 | TYR (0.57) | SLC7A5TYRDPP4HDAC8YARS1 | |
| SCHEMBL10934240 | 0.78 | TYR (0.65) | SLC7A5TYRDPP4HDAC8YARS1 | |
| SCHEMBL20898344 | 0.77 | MEN1 (0.35) | — | |
| SCHEMBL22075912 | 0.76 | TYR (0.40) | SLC7A5TYRDPP4HDAC8 | |
| SCHEMBL10575720 | 0.75 | SLC6A3 (0.43) | — | |
| SCHEMBL10800895 | 0.74 | SLC6A3 (0.42) | — | |
| SCHEMBL14363511 | 0.73 | KMT2A (0.45) | CA12CA1CA2CA9 | |
| SCHEMBL23454393 | 0.72 | DPP4 (0.43) | SLC7A5TYRDPP4HDAC8YARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0440777-B1 | BRAIN DERIVED NEUROTROPHIC FACTOR | MAX PLANCK GESELLSCHAFT (DE) | 1997-02-12 | — | — | EP | disclosed |
| US-5453361-A | Method for producing biologically active human brain derived neurotrophic factor | REGENERON PHARMACEUTICALS, INC. (US) | 1995-09-26 | — | — | US | disclosed |
| US-5187162-A | Methods of treating neurodegenerative conditions | GENSIA PHARMACEUTICALS (US) | 1993-02-16 | — | — | US | disclosed |
| US-5180820-A | Nucleic acid sequence code | REGENERON PHARMACEUTICALS, INC. | 1993-01-19 | — | — | US | disclosed |
| EP-0440777-A4 | BRAIN DERIVED NEUROTROPHIC FACTOR | — | 1992-05-13 | — | — | EP | disclosed |
| EP-0440777-A1 | BRAIN DERIVED NEUROTROPHIC FACTOR. | MAX PLANCK GESELLSCHAFT (DE) | 1991-08-14 | — | — | EP | disclosed |
| WO-1991003568-A1 | BRAIN DERIVED NEUROTROPHIC FACTOR | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1991-03-21 | — | — | WO | disclosed |